Table 3.
Clinical parameters of UC patients.
| UC | Number | Gender M/F % | Age | Lichtiger score | BM | QOL | |||
|---|---|---|---|---|---|---|---|---|---|
| Visit 1 | Visit 3 | Visit 1 | Visit 3 | Visit 1 | Visit 3 | ||||
| Cannabis | 9 | 4/5 | 40 ± 16 | 9.7 ± 1.2 | 4.9 ± 1.06* | 3.9 ± 1.2 | 1.7 ± 0.6* | 72.7 ± 6.7 | 98.2 ± 7.3* |
| Placebo | 10 | 8/2 | 34 ± 9 | 11.6 ± 0.9 | 8.4 ± 0.9*^ | 5.4 ± 1.8 | 3.7 ± 1.36* | 77.1 ± 3.7 | 82 ± 4.7^ |
Lichtiger score and BM and QOL levels in UC patients before and after cannabis/placebo use: UC patients were treated for 8 weeks with cannabis or placebo. At time 0 (visit 1) and 8 weeks following the cannabis or placebo use (visit 3), Lichtiger score, BM, and QOL levels were evaluated.
*Results significantly different from visit 1 (p < 0.05).
^Results significantly different between the placebo and the cannabis group (p < 0.05).